Indian emergency-use tocilizumab
Tocilizumab biosimilar developed by Firm name incomplete in the CDSCO list (Hyderabad). Reference product Actemra (RoActemra in the European Union).
About Indian emergency-use tocilizumab
An Indian company received a restricted emergency permission for its tocilizumab in October 2021, for use in COVID-19, at a time when the original product was in short supply. The published Indian list truncates the company's name, so the product is listed as it appears there. No routine permission for arthritis has followed in the published lists.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Chronology
- CDSCOOct 2021CDSCO permission granted
Sources
Planning tocilizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant